Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatology Other
    Severe Joint Pain in Multiple Areas Associated With Increased Risk of Falls in Older Adults - (DGNews)
    Rilonacept Approved in the EU for Cryopyrin-Associated Periodic Syndromes - (DGNews)
    Canakinumab Gives Faster, Greater Pain Relief in Refractory Gout Patients: Presented at ACR/ARHP - (DGDispatch)
    Previous Urate-Lowering Therapy Plus Febuxostat Lowers Urate Levels, Number of Flares in Patients With Gout: Presented at ACR/ARHP - (DGDispatch)

    News archive

     Recent webcasts/CME - Rheumatology Other
    Biologics and Infections: Common and Rare

    Webcasts/CME archive

     Recent cases - Rheumatology Other
      Pigmented Villonodular Synovitis of the Knee in a Patient on Oral Anticoagulation Therapy: A Case Report
      Rectal Mucosal Prolapse Syndrome as an Unusual Gastrointestinal Manifestation of Sjogren's Syndrome: A Case Report
      HELLP Syndrome, Multiple Liver Infarctions, and Intrauterine Fetal Death in a Patient with Systemic Lupus Erythematosus and Antiphospholipid Syndrome
      Nasal Septal Perforation in a Patient with Takayasu's Arteritis; a Rare Association
      Nummular Keratopathy in a Patient with Hyper-IgD Syndrome

      Cases archive
        




      my personal edition > rheumatology other > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Low-Dose Colchicine Eases Pain Due to Acute Gout Flare: Presented at ACR/ARHP

        By Jill Stein

        PHILADELPHIA -- October 23, 2009 -- Low-dose colchicine (Colcrys) provides a prompt improvement in the joint pain triggered by an acute gout flare, according to data released on October 19 at the 2009 Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP).

        The new results are derived from a secondary analysis of the phase 3 Acute Gout Flare Receiving Colchicine Evaluation (AGREE) trial.

        Robert Terkeltaub, MD, Veterans Affairs Medical Center, San Diego, California, and associates randomised 184 patients with gout to high-dose colchicine (1.2 mg, then 0.6 mg hourly x 6 hr = 4.8 mg total), low-dose colchichine (1.2 mg, then 0.6 mg in 1 hr = 1.8 mg total, followed by 5 placebo doses hourly), or placebo (2 capsules, then 1 capsule hourly x 6 hr).

        "The results provide the first evidence for the utility and tolerability of low-dose colchicine therapy in the treatment of acute gout flares," Dr. Terkeltaub said.

        The efficacy of low-dose (LD) colchicine (n = 74) was comparable to that of high-dose (HD) colchicine (n = 52) as evidenced by the following:
        · A similar percent of patients achieved at least a 2-unit decrease in target joint pain scores at 24 (HD group, 34.6%; LD group, 43.2%; P = .3298) and 32 hours (HD group, 38.5%; LD group, 45.9%; P = .4033).
        · A similar median time to 50% reduction in target joint pain (HD, 24.5 hr; LD, 24 hr).
        · A similar frequency of use of rescue medication.

        Both colchicine groups were statistically superior to placebo in terms of median time to 50% reduction in target joint pain, and both groups required fewer rescue medications.

        The side effect profile with low-dose colchicine was superior to high-dose colchicine and comparable to placebo.

        Colcrys, the only single-agent low-dose colchicine approved by the US Food and Drug Administration for the treatment of acute gout flares and familial Mediterranean fever, was recently approved for the prevention of gout flares.

        [Presentation title: Colchicine Efficacy Assessed by Time to 50% Reduction of Pain Is Comparable in Low-Dose and High-Dose Regimens: Secondary Analyses of the AGREE Trial. Abstract Number 1103]




      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send